Governance
Investors

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions.

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

 

May 21 2026
, ,

Deposito del Verbale dell’Assemblea degli Azionisti

More details
May 12 2026
, ,

Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026

more details
May 12 2026
, ,

The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)

more detalis
May 06 2026
, ,

Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026

Dr. Ettore Gilardoni will present a poster entitled "Mass Spectrometry–Based Atlas of the Blood-Accessible Surface Proteome in Syngeneic Brain Tumor Models". Follow the...
May 06 2026
, ,

Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

Prof. Philipp Backhaus will give a presentation on “Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [68Ga]Ga-OncoACP3-DOTA PET and first experience with...
May 06 2026
, ,

Philogen to attend the Summer School in Pharmaceutical Analysis, 21-23 September 2026

Dr. Ettore Gilardoni is giving a lecture entitled "Mass Spectrometry Applications For Targets And Hit Compounds Identification". Follow the link for more details
May 06 2026
, ,

Philogen to attend the Festival of Biologics, 13-15 October 2026

Dr. Ettore Gilardoni will give an oral presentation entitled "Charge Variants characterization of a noncovalent dimeric fusion protein". Follow the link for more...
Apr 29 2026
, ,

L’Assemblea degli Azionisti di Philogen S.p.A. ha approvato il bilancio 2025

more details
Apr 17 2026
, , ,

Philogen to attend EADO 2026, 23-25 April 2026

Prof. Thomas Eigentler will give a talk entitled "Intralesional L19IL2/L19TNF in high-risk lacSCC patients: results from the Phase II DUNCAN Trial Exploratory Cohort"....
Apr 08 2026
, ,

Avviso di pubblicazione della documentazione relativa all’Assemblea degli Azionisti convocata per il 29 aprile 2026

more details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions